Finally, we assessed the role of CCND1 amplification in a pan-cancer context in MSK1600 and found a significant association with reduced overall survival in CPI-treated patients (HR = 2.0 [1.4–2.9], p = 3.3 × 10−4) (Figure 6F), but not the non-CPI-treated MSK cohort (p = n.s., which is a larger cohort with arguably greater power) (Figure 6G). This evidence concerns the gene CCND1 and cancer.